Stemi India Competitors

Innotech Control Systems design, manufacture and service Heating, Ventilation and Air Conditioning (HVAC), Environmental Control, and Building Automation/Management Systems (BAS/BEMS/BMS) since 1984. In that time, we have developed an award-winning inventory of high quality products. We combine this with friendly and practical advice from our dedicated team of professionals. In order to meet the demand for our vast range of products and services, we are supported by a network of local and international distributors.

Trilogy Innovations is an enterprise technology reseller and solution provider division of Trilogy Leasing Co., LLC. We have developed partnerships with industry-leading manufacturers as well as the best of the emerging manufacturers. Our unique Technology Portfolio gives our customers the richest choice of solutions that more effectively solve their business and technology challenges. Trilogy’s technology portfolio was initially developed with a broad selection across all of the industry sectors to provide maximum benefit to our Federal Government customers. We have adapted that approach to also bring our expansive portfolio and knowledge base to customers in the State and Local Government and general Commercial sectors within the US. Now all our customers can benefit from our best-of-breed technology solutions.the richest choice of technology solutions that more effectively solve their business and technology challenges. Trilogy's technology portfolio was initially developed with a broad selection across all of the technology industry sectors to provide maximum benefit to our Federal Government customers. We have adapted that approach to also bring our expansive portfolio and knowledge base to customers in the State and Local Government and general Commercial sectors within the US. Now all of our customers can benefit from our best-of-breed technology solutions.

APEX is a patient-driven pharmaceutical company focused on optimizing the standard of mental health care with psilocybin by bringing data supported, clinically evaluated drugs to market for depression and anxiety in PTSD. Our strategy is focused on developing pharmaceutical products through a phased clinical program evaluating safety and efficacy across multiple indications, alongside a robust early access program. APEX has two GMP Certified drug assets. APEX-52 is microdose synthetic psilocybin for clinical evaluation, currently in active phase 2b trials, and APEX-25 is the company’s macro dose drug asset, developed for in-clinic dosing with assisted psychotherapy. APEX recently launched North America’s first take-home psilocybin trial, and received approval for the world’s largest psilocybin clinical trial to-date both evaluating APEX-52 in the treatment of anxiety and depression in diagnosed PTSD. APEX is driven by an experienced and passionate leadership team from the Veteran community, healthcare, drug policy and emerging sectors who want to make a difference and disrupt the $380+ billion global mental health market. Find out more at apexlabs.com